Articles tagged with Breast Cancer
Researchers at Michigan Medicine identified a promising new compound for targeting triple-negative breast cancer. UM-164 blocks the kinase c-Src and inhibits another pathway, p38, involved in this subtype. The compound had very few side effects in mice.
A study led by Loyola Medicine researchers found that taking tamoxifen for breast cancer reduces the risk of uterine cancer in postmenopausal patients. The study also showed that a normal ultrasound before treatment may provide additional reassurance.
LA BioMed researchers find a new study on aromatase inhibitors to prevent breast cancer recurrence is reassuring. The study's findings have direct application for clinical practice, with implications for cardiologists and oncologists.
A new study from MD Anderson Cancer Center found substantial variation in costs of breast cancer treatment for different chemotherapy regimens, with insurer costs varying by as much as $20,354. Choosing equally effective but less costly regimens could impact the cost of breast cancer care nationally by $1 billion every year.
A crowd-sourcing strategy leveraging social media and advocacy groups has connected over 2,000 patients from all 50 states with the Metastatic Breast Cancer Project. This approach empowers patients to directly participate in research, improving outcomes for advanced breast cancer patients.
Researchers found that patients who used metformin before diagnosis had a higher risk of death, while those who started using it after diagnosis were more likely to survive. Metformin also showed promise as a treatment for endometrial hyperplasia, with 56% of patients responding to treatment.
Researchers have discovered a new protein compound that binds to two HER2 receptors simultaneously, preventing growth signals and killing cancer cells. This innovative solution shows great promise in treating invasive breast cancer more effectively.
A new treatment shows promise against a rare and deadly eye cancer by blocking the protein ARF6, which distributes cancer-promoting signals. The study found that inhibiting ARF6 inhibited eye tumors in mice, suggesting a potential strategy for treating other cancers as well.
An international clinical trial led by University of Pittsburgh Cancer Institute (UPCI) professor Atilla Soran found that surgery to remove the primary tumor followed by standard therapy adds months to patients' lives compared to standard therapy alone. Surgery resulted in nearly 42% of women living to five years after diagnosis.
A new compound called Fasnall has been discovered to impede the proliferation of breast cancer cells in mice. By inhibiting the normal activity of fatty acid synthase, an enzyme that regulates cell growth and proliferation, Fasnall also contributed to the death of existing cancer cells.
New research suggests that fluctuations in tRNA levels can have a dramatic impact on cellular function, driving metastatic breast cancer. The study found that two specific tRNAs were associated with increased metastasis, leading to changes in gene expression and protein production.
A new study from Mount Sinai researchers reports a high success rate for a personalized medicine program that uses an integrated genomic approach to guide cancer treatment. The program led to therapeutic recommendations for 91% of patients, outperforming targeted cancer panels in clinical use.
The BRCA1 gene's ubiquitin ligase activity is crucial for error-free DNA repair through homologous recombination. Cells lacking this function are sensitive to DNA damaging agents and may develop cancer.
A study by Dr. Sarah Saxena found that breast cancer patients need fewer painkillers after non-opiate anesthesia, which may reduce side effects like nausea and vomiting. Non-opiate anesthesia could also potentially lower cancer recurrence rates, but further research is needed to confirm these findings.
New research suggests that women with a high genetic risk of breast cancer can reduce their risk by following a healthy lifestyle, including eating right, exercising, and quitting smoking. The study found that approximately 30% of breast cancer cases could be prevented by modifying known risk factors.
Researchers developed a model to estimate absolute breast cancer risk, finding that up to 28.9% of breast cancers could be prevented by reducing modifiable risk factors in white US women. The study included 92 genetic susceptibility variants and various epidemiologic factors.
SWOG investigators report on clinical trials for lung, prostate, breast, and other cancers, including Lung-MAP precision medicine trial. Trial results also highlight the reliability of CT scan tumor measurements for evaluating new drug effectiveness.
A recent study published in The Lancet found that the global economic crisis was associated with an increase in cancer mortality, particularly among treatable cancers. Universal health care coverage may protect patients from the health consequences of rising unemployment and reduced public-sector healthcare spending.
A multi-institutional team has completed the first large-scale proteogenomic study of breast cancer, linking DNA mutations to protein signaling and identifying genes that drive cancer. The study highlights the power of integrating genomic and proteomic data to yield a more complete picture of cancer biology.
A phase I clinical trial showed that abemaciclib achieved durable clinical activity in patients with breast cancer, non-small cell lung cancer, glioblastoma, and melanoma. Radiographic responses were observed for some patients with hormone receptor-positive breast cancer and NSCLC.
A prospective economic study published in Annals of Internal Medicine found that computed tomographic angiography and functional diagnostic testing strategies for diagnosing coronary artery disease have similar costs through 3 years of follow-up. The study included 9,649 patients enrolled in a clinical trial between 2010 and 2013.
Researchers at Boston University School of Medicine found similarities in genetic and epigenetic alterations between breast and ovarian cancers. The study suggests that better understanding of these changes may lead to more effective chemotherapeutics and strategies to circumvent drug resistance.
Researchers at Sylvester Comprehensive Cancer Center identified a novel treatment option for triple-negative breast cancer (TNBC) by targeting vitamin D and androgen receptors. This approach showed promising results in reducing the sustainability of cancer cells, offering new hope for patients with this aggressive form of breast cancer.
Researchers at Dana-Farber Cancer Institute present studies on the influence of tumor location on colorectal cancer survival, breast cancer clinical trial participation among older patients, and support for medical marijuana use in children with cancer. The findings suggest that consistent reporting of tumor location is crucial for imp...
A study published in Cancer Epidemiology, Biomarkers & Prevention found that adolescent girls with high saturated-fat diets and low unsaturated-fat intake had higher breast densities, which may increase their risk for breast cancer later in life. The researchers analyzed data from 177 women and observed a significant association betwee...
A research team identified low expression of methylation-controlled J protein (MCJ) as a marker of poor response to chemotherapy in triple-negative breast cancer patients. They found that MCJ-expressing tumors had reduced relapse-free survival and that mice deficient in MCJ had larger tumors and increased chemoresistance.
Researchers have developed a single-layer organic nanometer-scale transistor that can detect molecules associated with neurodegenerative diseases and some types of cancer. The device uses glutathione and glutathione S-transferase to identify target molecules, offering sensitivity and potential for rapid diagnosis.
A recent study by Johns Hopkins Kimmel Cancer Center scientists reveals that the HOXA5 protein plays a crucial role in maintaining normal breast cells' traits, such as adhesion and cell plasticity. The loss of HOXA5 leads to increased tumor aggressiveness and poorer outcomes for patients.
A study published in Cancer Epidemiology, Biomarkers & Prevention found that consuming high amounts of saturated fat or low amounts of mono- and polyunsaturated fats during adolescence is associated with higher breast density in young adulthood. This increased risk of breast cancer was observed after adjusting for multiple variables.
A new study using mice and lab-grown human cells shows a triple-drug cocktail can shrink triple-negative breast cancers by killing off cancer cells and halting new tumor growth. The combination treatment, EAD therapy, reduced the size of tumors in mice and decreased tumor growth in spheres grown from patients' metastatic cells.
Researchers designed a novel mTOR inhibitor, Rapalink, to combat drug-resistant tumors. In animal experiments, Rapalink reduced the size of tumors resistant to earlier-generation inhibitors.
VIPA-based Brillouin spectroscopy enables accurate tissue stiffness measurement by suppressing unwanted light noise. The technique allows for noninvasive biological characterization of materials like chicken breast or potentially cancerous tumors.
A novel therapeutic approach has been discovered using a breast cancer drug to treat acute myeloid leukemia (AML) patients with FLT3 mutations. The compound blocks the production of the FLT3 gene and subsequently downregulates its activity, leading to the death of cancer cells.
A recent study found that minority and less educated women perceive breast cancer as a more common killer than heart disease, which may contribute to worse health outcomes. Researchers recommend that healthcare providers incorporate messages for both breast health and heart disease prevention to maximize impact.
Breast cancer tumor-initiating cells use mTOR signaling to recruit myeloid-derived suppressor cells (MDSCs), which are involved in suppressing the body's response against tumors. This interaction helps researchers understand the events leading to tumor growth and metastasis, identifying potential therapeutic targets.
Researchers at SISSA have developed a gene therapy approach targeting glioblastomas by introducing an active version of the Emx2 gene, which inhibits astrocyte growth and leads to tumour cell suicide. The treatment has demonstrated efficacy in both vitro and in vivo tests, with potential for preventing aggressive recurrence development.
Researchers have identified a promising approach to treating triple-negative breast cancer (TNBC) by targeting the MYC oncogene. The study found that selective killing of MYC-overexpressing TNBC cells can be achieved through inhibition of cell cycle progression and fatty acid oxidation.
SmartPractice has donated $50,000 to TGen to support the development of liquid biopsies, which can detect breast cancer earlier and more precisely. The donation aims to identify genetic biomarkers in blood that could help prevent cancer from spreading.
Women with early-stage breast cancer who used dietary supplements and complementary therapies were less likely to start chemotherapy. Dietary supplement usage was associated with a lower likelihood of initiating chemotherapy, while mind-body practices showed no relation.
Women with early-stage breast cancer who used dietary supplements and complementary medicine were less likely to start chemotherapy than nonusers, according to a new study. CAM use was associated with lower chemotherapy initiation rates among those for whom treatment was indicated.
Researchers at the University of Birmingham successfully trained breast cancer patients to achieve single prolonged breath holds of over five minutes, enabling targeted radiotherapy to be administered in just one dose. This breakthrough could improve long-term survival and quality of life for breast cancer patients.
A study published in JAMA found that longer periods of film readers interpreting screening mammograms did not result in a reduced rate of breast cancer detection. The researchers investigated the impact of changing the order in which two experts examined digital mammograms on cancer detection rates, but found no significant difference.
Researchers have identified 40 mutated genes that contribute to breast cancer progression, with one gene, PIK3CA, found to lower survival chances for three subtypes. The study's findings could help develop targeted treatments and improve diagnostic tests.
A study by Dr Sian Taylor-Phillips and her team found no decline in mammogram readers' accuracy, despite previous theories suggesting a 'vigilance decrement.' The researchers analyzed 1.2 million women's x-rays and found that cancer detection rates stayed constant throughout each batch of approximately 35 readings.
Research published in BMJ Open found that single dose targeted intraoperative radiotherapy can save patients thousands of hours of time, journeys, and CO2 emissions compared to standard treatment. The study estimates that widespread adoption of TARGIT could save millions of miles, tons of CO2, and hundreds of hours of travel time annually
A new study uses multiplexed immunostaining to examine protein expression in breast tumors, identifying clusters of co-expressed proteins within cancer cells. This technique enhances our understanding of tumor biology and signaling networks.
A new study published in the Journal of Clinical Sleep Medicine found that women who slept less than 7 hours per night and were frequent snorers before their cancer diagnosis had a poorer prognosis. The study suggests that poor sleep quality may contribute to accelerated tumor growth and shortened cancer survival.
A new study by researchers at the University of Pennsylvania's Abramson Cancer Center found that testing non-breast cancer genes in high-risk women does not add clinical benefit. The study analyzed a large panel of genes and found that many variants were of uncertain significance, adding complexity to genetic counseling.
Researchers at Duke University Medical Center have developed an antibody that selectively attacks cancer cells while sparing healthy ones. The antibody works by targeting a specific protein on cancer cells, disabling their defense mechanism and triggering an immune response.
Research suggests mango's anti-obesity, anti-cancer, anti-inflammatory, and intestinal health roles. Studies in mice and humans reveal potential benefits of mango consumption on body composition, glucose homeostasis, and gut inflammatory markers.
A new study suggests that cognitive-behavioral therapy can help prevent long-term memory issues caused by chemotherapy. The therapy, called Memory and Attention Adaptation Training (MAAT), was developed to increase awareness of situations where memory problems arise and develop skills to compensate for memory dysfunction.
Researchers have discovered that a combination of 5-azacytidine and the HDAC inhibitor butyrate reduces the number of cancer stem cells in breast cancer patients. This targeted approach may improve survival rates and provide a new treatment option for breast cancer.
The study uncovered five new genes associated with breast cancer and 13 new mutational signatures that influence tumour development. The analysis revealed the genetic variations in breast cancers and their distribution across the genome.
A new study found that younger women with early breast cancer who undergo breast conserving therapy (BCT) have a 13% higher risk of local recurrence and a doubled risk of metastasis compared to those who receive mastectomy. This contrasts with older women, where BCT is deemed safe without increased risks.
A study published in Plastic and Reconstructive Surgery found that DIEP flap breast reconstruction provides good long-term quality of life for women who have undergone mastectomy for breast cancer. The reconstruction method allowed patients to maintain a good QOL in the long-term, comparable to women without breast cancer.
A large number of Phase III radiotherapy trials failed to publish their results, exposing patients to unnecessary risks. Researchers found that only 47% of eye cancer trials were published, while 100% of testicular and anal cancer trials went unpublished.
A new study has identified a long non-coding RNA that plays a crucial role in the repair of DNA breaks in triple-negative breast cancer cells. The research found that blocking this RNA significantly increases sensitivity to radiation therapy, providing new insight into the biology of this tough-to-treat breast cancer subtype.
Researchers at Scripps Research Institute identify structural changes in estrogen receptor binding molecules linked to regulating cancer growth. The study reveals predictive features of ligand-specific signaling through the receptor, moving closer to developing more effective treatments for breast cancer.
A new gene testing technology has been developed to identify mutations and prioritize variants in breast and ovarian cancer genes. The method reveals gene variants that were missed by conventional genetic testing, increasing the number of patients that can be properly diagnosed.
A study published in JAMA found that adding tomosynthesis to digital mammography significantly increased cancer detection rates and reduced recall rates for women with dense breasts. The findings suggest that supplemental breast cancer screening using tomosynthesis may improve outcomes for women with varying levels of breast density.